Carbamazepine and Daridorexant interaction

Carbamazepine and Daridorexant: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Carbamazepine (EQUETRO) label · effective 2025-08-19

Major

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope.

Drug interactionsby drug classView label on DailyMed
Moderate

Consider reducing the dose of CNS depressants or EQUETRO when using these drugs concomitantly.

Drug interactionsby drug classView label on DailyMed
Minor

Cytochrome (CYP) 3A4 inhibitors, epoxide hydrolase inhibitors, CYP3A4 inducers, drugs metabolized by CYP1A2 or CYP3A4 (oral contraceptives, delavirdine, nefazodone), phenytoin, CNS depressants, lithium, chloroquine, mefloquine ( 7.1 , 7.2 , 7.3 )

Drug interactionsby drug classView label on DailyMed
Minor

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants.

Drug interactionsby drug classView label on DailyMed

From the Daridorexant (QUVIVIQ) label · effective 2026-02-26

Major

Moderate or Strong CYP3A4 inducers: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management: Concomitant use of QUVIVIQ with a strong or moderate inducer of CYP3A4 is not recommended [see Dosage and Administration (2.2) ] .

Drug interactionsby drug classView label on DailyMed
Moderate

Risk increases when used with other central nervous system (CNS) depressants.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Strong and Moderate CYP3A4 Inducers Clinical Implications: Concomitant use with a strong or moderate CYP3A4 inducer decreases exposure to daridorexant [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of QUVIVIQ.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.